ATXN3-Targeting Oligonucleotides for SCA3 Aggregate Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective treatments for neurodegenerative diseases such as spinocerebellar ataxia type 3 (SCA3), which are characterized by progressive cerebellar ataxia and the formation of toxic protein aggregates, with current management being largely supportive and not slowing the disease progression.
Innovation Solution
Development of compounds and pharmaceutical compositions that reduce the expression of ATXN3 mRNA and Ataxin-3 protein, including oligomeric compounds and modified oligonucleotides, to target and decrease the formation of protein aggregates and ameliorate symptoms like ataxia and neuropathy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current supportive management is used for SCA3, then patient comfort is maintained, but disease progression is not slowed and motor function continues to deteriorate
Solution Approach 1:
The patent extracts and targets the specific pathological element (ATXN3 mRNA and toxic ataxin-3 protein) responsible for disease progression. By using antisense oligonucleotides that specifically bind to and reduce ATXN3 mRNA expression, the treatment removes the toxic protein source without affecting other physiological processes, thereby slowing disease progression while maintaining targeted simplicity.
Solution Approach 2:
The patent changes the molecular parameter of ATXN3 mRNA expression levels by introducing antisense oligonucleotides that bind to and reduce mRNA translation. This parameter change directly reduces toxic ataxin-3 protein production, addressing the core pathological mechanism while providing a targeted therapeutic approach that differs from broad-spectrum supportive care.
2Object-generated harmful factors
If oligomeric compounds and modified oligonucleotides are used to reduce ATXN3 mRNA expression, then toxic protein aggregate formation is decreased, but the complexity of the treatment increases
Solution Approach 1:
The patent uses antisense oligonucleotides as intermediary molecules that mediate between the administered treatment and the target ATXN3 mRNA. These oligonucleotides specifically bind to mRNA through complementary base pairing, acting as a targeted intermediary that reduces toxic protein production without requiring complex delivery systems or affecting non-target proteins.
Solution Approach 2:
The patent replaces mechanical or surgical interventions with a molecular-level chemical mechanism. Instead of physical support or invasive procedures, the treatment uses antisense oligonucleotides that chemically bind to and reduce mRNA expression, substituting a sophisticated molecular mechanism for simpler but less effective mechanical supportive care.
3Ease of operation
If supportive care medications are administered, then specific symptoms like spasticity and dystonia are managed, but the underlying neurodegenerative process continues unchanged
Solution Approach 1:
The patent takes preliminary action by targeting and reducing ATXN3 mRNA expression before extensive neurodegeneration occurs. By using antisense oligonucleotides to lower toxic protein levels early in the disease course, the treatment prevents further neuronal damage and aggregates formation, addressing the root cause rather than waiting for symptoms to manifest and requiring palliative management.
Solution Approach 2:
The patent inverts the traditional symptomatic treatment approach by targeting the molecular cause (ATXN3 mRNA and toxic protein) rather than the downstream symptoms. Instead of managing spasticity and dystonia with medications, the treatment works in reverse by reducing the toxic protein that causes these symptoms, thereby addressing the disease mechanism rather than its manifestations.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed compounds and compositions effectively reduce the amount of Ataxin-3 protein, leading to improved motor function and decreased aggregate formation, thereby ameliorating symptoms of SCA3.
Implementation Method 1
The modified oligonucleotide is hybridized to a complementary sequence of the ATXN3 mRNA
Implementation Method 2
The modified oligonucleotide comprises at least one modified nucleoside comprising a bicyclic sugar moiety and a phosphorothioate internucleoside linkage and is capable of hybridizing to a complementary sequence of the ATXN3 mRNA and reducing the amount or activity of the ATXN3 mRNA in a cell
Data Source
AI summary
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN3 mRNA in a cell or animal, and in certain instances reducing the amount of Ataxin-3 protein in a cell or animal. Such compounds, methods, and pharmaceutical compositions are useful to prevent or ameliorate at least one symptom or hallmark of a neurodegenerative disease. Such symptoms and hallmarks include ataxia, neuropathy, and aggregate formation. Such neurodegenerative diseases include SCA3.